Table 1.
Baseline characteristics between micro-nutrient deficiency group and non-deficiency group
| Variables | Total (n = 205) | Micro-nutrient deficiency group (n = 80, 39.0%) | Non-deficiency group (n = 125, 61.0%) | P-value |
|---|---|---|---|---|
| Male sex | 118 (57.6) | 44 (55.0) | 74 (59.2) | 0.553 |
| Age | 34 (19–47) | 27 (19–41) | 37 (20–51) | 0.003 |
| The path of laboratory test | 0.150 | |||
| Outpatients clinic | 191 (93.2) | 72 (90.0) | 119 (95.2) | |
| Hospitalization patients | 14 (6.8) | 8 (10.0) | 6 (4.8) | |
| Number of micronutrient tests | ||||
| Folate | 127 (62.0) | 64 (80.0) | 63 (50.4) | < 0.001 |
| Vitamin B12 | 128 (62.4) | 64 (80.0) | 64 (51.2) | < 0.001 |
| 25-OH-vitamin D | 184 (90.2) | 67 (83.8) | 117 (94.4) | 0.013 |
| Ferritin | 97 (47.3) | 48 (60.0) | 49 (39.2) | 0.004 |
| Type of IBD | 0.003 | |||
| UC | 49 (23.9) | 9 (11.3) | 40 (32.0) | |
| CD | 143 (69.8) | 66 (82.5) | 77 (61.6) | |
| Intestinal BD | 13 (6.3) | 5 (6.3) | 8 (6.4) | |
| Medications | ||||
| 5-ASA | 114 (55.6) | 33 (41.3) | 81 (64.8) | 0.001 |
| Steroids | 12 (5.9) | 3 (3.8) | 9 (7.2) | 0.305 |
| Azathioprine | 66 (32.2) | 32 (40.0) | 34 (27.2) | 0.056 |
| Anti-TNF | 101 (49.3) | 45 (56.3) | 56 (44.8) | 0.110 |
| Methotrexate | 33 (16.1) | 11 (13.8) | 22 (17.6) | 0.464 |
| 6-MP | 2 (1.0) | 0 (0) | 2 (1.6) | 0.256 |
| Othersa | 12 (5.9) | 2 (2.5) | 10 (8.0) | 0.102 |
| Supplementary medications | ||||
| Iron supplementation | 77 (37.6) | 43 (53.8) | 34 (27.2) | < 0.001 |
| Folate supplementation | 50 (24.4) | 26 (32.5) | 24 (19.2) | 0.031 |
| Multivitamin | 52 (25.4) | 21 (26.3) | 31 (24.8) | 0.816 |
| Calcium, Vitamin D supplementation | 127 (62.0) | 51 (63.7) | 76 (60.8) | 0.671 |
| Vitamin B12 supplementation | 43 (21.0) | 30 (37.5) | 13 (10.4) | < 0.001 |
| Vitamin C supplementation | 3 (1.5) | 0 (0) | 3 (2.4) | 0.163 |
| Zinc supplementation | 7 (3.4) | 3 (3.8) | 4 (3.2) | 0.832 |
| Osteoporosis medication | ||||
| SERM | 3 (1.5) | 1 (1.3) | 2 (1.6) | 0.839 |
| Bisphosphonate | 14 (6.8) | 1 (1.3) | 13 (10.4) | 0.011 |
| Operation | 65 (31.7) | 33 (41.3) | 32 (25.6) | 0.019 |
| Underlying disease | ||||
| Hypertension | 4 (2.0) | 1 (1.3) | 3 (2.4) | 0.561 |
| Diabetes | 1 (0.5) | 0 (0) | 1 (0.8) | 0.423 |
| Osteoporosis | 38 (18.5) | 13 (16.3) | 25 (20.0) | 0.500 |
| Othersb | 46 (22.4) | 19 (23.8) | 27 (21.6) | 0.719 |
Data are expressed as median (interquartile range, IQR) or n (%). *P-value for comparing patients with micronutrient deficiency group and non-deficiency group
IBD, Inflammatory bowel disease; UC, Ulcerative colitis; CD, Crohn’s disease; BD, Behçet’s disease; 5-ASA, 5-aminosalicylic acid; anti-TNF, anti-tumor necrosis factor; 6-MP, 6-mercaptopurine; SERM, Selective estrogen receptor modulators
aMongersen, vedolizumab
bMyelodysplastic syndrome, Systemic lupus erythematosus, aortic valve disease, Bronchiolitis obliterans with organizing pneumonia, osteoarthritis, coronary artery occlusive disease, cancer